PHASE II STUDY OF IMATINIB MESYLATE (PMS) IN NEUROFIBROMATOSIS TYPE I PATIENTS AGED 2 TO 21 WITH PLEXIFORM NEUROFIBROMAS

Registry ID

PLNEU SJ 01

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE

Start date

2014-06-23

Last update

2013-12-31

Conditions

• NEUROFIBROMATOSIS TYPE I
• PLEXIFORM NEUROFIBROMAS

Related clinical trials

• A PHASE III, MULTICENTRE, INTERNATIONAL STUDY WITH A PARALLEL, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, 2 ARM DESIGN TO ASSESS THE EFFICACY AND SAFETY OF SELUMETINIB IN ADULT PARTICIPANTS WITH NF1 WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (KOMET)
• A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA OR PLEXIFORM NEUROFIBROMA WITH REFRACTORY TUMOR AND ACTIVATION OF THE MAPK/ERK PATHWAY

View on source registry